AstraZeneca Plc Confident Over Revenues Until 2017

In this investing video, Owain Bennallack explains why he believes that AstraZeneca’s (LSE: AZN) (NYSE: AZN.US) statement that it expects to maintain 2013’s level of revenues to 2017 isn’t as downbeat as investors may initially think, and why both Astra and GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) are coming back into favour…

If you're wondering where to put your money, then check out our brand-new special free report, "How To Create Dividends For Life". The report gives you five golden rules for building your portfolio, is completely free and comes without any obligations. So don't delay -- click here to receive it now!

> Owain owns shares in AstraZeneca and GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.